These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6431661)

  • 1. Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate.
    Horowitz B; Lippin A; Chang MY; Shulman RW; Vandersande J; Stryker MH; Woods KR
    Transfusion; 1984; 24(4):357-62. PubMed ID: 6431661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of antihemophilic factor from indated plasma.
    Wickerhauser M
    Transfusion; 1976; 16(4):345-50. PubMed ID: 951729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma fibronectin concentrations in blood products.
    Perttilä J; Salo M; Peltola O
    Intensive Care Med; 1990; 16(1):41-3. PubMed ID: 2107234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microwave-thawed plasma for cryoprecipitate production.
    Bass H; Trenchard PM; Mustow MJ
    Vox Sang; 1985; 48(2):65-71. PubMed ID: 3934842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibronectin in liquid and frozen stored blood components.
    Snyder EL; Ferri PM; Mosher DF
    Transfusion; 1984; 24(1):53-6. PubMed ID: 6420955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A protocol for the preparation of cryoprecipitate and cryodepleted plasma.
    Sparrow RL; Greening DW; Simpson RJ
    Methods Mol Biol; 2011; 728():259-65. PubMed ID: 21468954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reticuloendothelial (RE) response to surgery as modified by intravenous administration of plasma cryoprecipitate or cold-insoluble globulin (plasma fibronectin) purified by affinity chromatography.
    Saba TM; Cho E
    Adv Shock Res; 1980; 3():251-71. PubMed ID: 6795905
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
    Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
    Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of factor VIII-rich cryoprecipitate and the plasma fibronectin-rich, heparin-precipitable fraction prepared from single-donor plasma units.
    Menitove JE; Amrani DL; Meh D; Frenzke M; Mosesson MW
    Transfusion; 1987; 27(6):491-5. PubMed ID: 3500532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive loss of fibronectin-mediated opsonic activity in plasma cryoprecipitate with storage. Role of fibronectin fragmentation.
    Blumenstock FA; Valeri CR; Saba TM; Cho E; Melaragno A; Gray A; Lewis M
    Vox Sang; 1988; 54(3):129-37. PubMed ID: 3369134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor.
    Wickerhauser M; Mercer JE; Eckenrode JW
    Vox Sang; 1978; 35(1-2):18-31. PubMed ID: 664566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Research Analysis.
    Sparrow RL; Simpson RJ; Greening DW
    Methods Mol Biol; 2023; 2628():41-49. PubMed ID: 36781778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of fibronectin and opsonic deficiency in patients. A controlled study.
    Saba TM; Blumenstock FA; Shah DM; Kaplan JE; Cho E; Scovill W; Stratton H; Newell J; Gottlieb M; Sedransk N
    Ann Surg; 1984 Jan; 199(1):87-96. PubMed ID: 6362585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma.
    Vermeer C; Soute BA; Ates G; Brummelhuis HG
    Vox Sang; 1976; 30(1):1-22. PubMed ID: 1251567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Human plasma fibronectin. Comparison of methods for preparation of a concentrate for therapeutic use from different sources].
    Regnault V; Rivat C; Geschier C; Stoltz JF
    Rev Fr Transfus Hemobiol; 1990 Dec; 33(6):391-405. PubMed ID: 2285448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severely heated therapeutic factor VIII concentrate of high specific activity.
    Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
    Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of cryoprecipitated factor VIII concentrates.
    Slichter SJ; Counts RB; Henderson R; Harker LA
    Transfusion; 1976; 16(6):616-26. PubMed ID: 996922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.
    Mazurier C; Samor B; Deromeuf C; Goudemand M
    Thromb Res; 1985 Mar; 37(6):651-8. PubMed ID: 3922084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield.
    Wensley RT; Snape TJ
    Vox Sang; 1980; 38(4):222-8. PubMed ID: 6774480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.